Most Read Articles
Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

19 Jun 2019
Slideshow: Highlights from the Asian Pacific Society of Cardiology 2019 Congress
Yesterday
A study has recently derived and validated a new index for preoperative cardiovascular evaluation, which can significantly contribute to the efficient triage and management of patients scheduled for noncardiac surgery. The new Cardiovascular Risk Index (CVRI) demonstrates a robust discriminatory power that can effectively stratify patients into low-, intermediate- and high-risk groups.
04 Jun 2019
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.

Uric acid tied to cardiometabolic risk factors in overweight, obese youths

14 Sep 2018

Uric acid is positively associated with blood pressure, insulin and triglycerides in overweight and obese youths, reports a study. A relevant clustering of metabolic risk factors occur as uric acid levels increase, while the risk factor that is less frequently present is elevated blood pressure (BP).

Among participants, boys had significantly higher uric acid than girls. Uric acid showed a positive, significant association with office, daytime and night-time systolic (S)BP, insulin, and triglycerides.

There was a progressive increment in body mass index (BMI), waist circumference, BMI z score, fasting insulin and HOMA index after stratification by sex-specific uric acid tertiles. Such increment was also observed in office and ambulatory SBP among boys.

Similarly, there was an increase in the number of abnormal metabolic risk factors with the uric acid values. The higher the number of metabolic components, the higher the uric acid values.

Furthermore, multiple regression analysis revealed that uric acid significantly correlated with male sex, waist circumference, both office and night-time SBP, and birth weight.

“Further studies need to assess the mechanistic link between uric acid and the cardiometabolic risk factors,” the authors said.

To examine the link between uric acid and individual cardiometabolic risk factors, as well as their degree of clustering, 333 Caucasians of both sexes (149 women; aged 5–18 years) who underwent an assessment of overweight/obesity were recruited. The authors measured anthropometric parameters, office and 24-hour BP measurement and metabolic profiles, including HDL-cholesterol, triglycerides, insulin, HOMA index and uric acid.

“Observational studies have indicated that high levels of serum uric acid are associated with the risk of cardiovascular disease,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

19 Jun 2019
Slideshow: Highlights from the Asian Pacific Society of Cardiology 2019 Congress
Yesterday
A study has recently derived and validated a new index for preoperative cardiovascular evaluation, which can significantly contribute to the efficient triage and management of patients scheduled for noncardiac surgery. The new Cardiovascular Risk Index (CVRI) demonstrates a robust discriminatory power that can effectively stratify patients into low-, intermediate- and high-risk groups.
04 Jun 2019
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.